New Zealand Markets closed

Bayer profit flat as weak animal health offsets strong Xarelto

Bayer's adjusted core earnings were flat for the quarter, as better prescription numbers for cardiovascular drug Xarelto were tempered by a weaker animal health business and a strong euro weighing on the value of overseas sales. Sonia Legg reports.